Smokeless tobacco (moist snuff) use and the risk of developing rheumatoid arthritis: Results from a case-control study

Arthritis Care and Research

Volumn 66, Issue 10, 2014, Pages 1582-1586

  Jiang, Xia ^a   Alfredsson, Lars ^c   Klareskog, Lars ^b   Bengtsson, Camilla ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM COUNTY COUNCIL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; NICOTINE; AUTOANTIBODY; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; CONTROLLED STUDY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY NEGATIVE RHEUMATOID ARTHRITIS; CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE RHEUMATOID ARTHRITIS; EXPOSURE; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; RESIDENTIAL AREA; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SMOKELESS TOBACCO; SMOKING; SMOKING CESSATION; ARTHRITIS, RHEUMATOID; BLOOD; CASE CONTROL STUDY; IMMUNOLOGY; RISK; RISK FACTOR; STATISTICAL MODEL; SWEDEN; TIME;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; HUMANS; LOGISTIC MODELS; ODDS RATIO; PEPTIDES, CYCLIC; RISK ASSESSMENT; RISK FACTORS; SMOKING; SWEDEN; TIME FACTORS; TOBACCO, SMOKELESS;

EID: 84908499489     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22325     Document Type: Article

References (20)

1. Costenbader KH, Feskanich D, Mandl LA, Karlson EW. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med 2006;119:503.e1-9.
2. Karlson EW, Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals. Arthritis Rheum 1999;42:910-7.
3. Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I, Klareskog L, et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis 2003;62:835-41.
4. Kallberg H, Padyukov L, Plenge RM, Ronnelid J, Gregersen PK, van der Helm-van Mil AH, et al. Gene-gene and geneenvironment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007;80:867-75.
5. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006;54:38-46.
6. Sopori ML, Kozak W. Immunomodulatory effects of cigarette smoke. J Neuroimmunol 1998;83:148-56.
7. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol 2002;2:372-7.
8. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003;421:384-8.
9. Fant RV, Henningfield JE, Nelson RA, Pickworth WB. Pharmacokinetics and pharmacodynamics of moist snuff in humans. Tob Control 1999;8:387-92.
10. Foulds J, Ramstrom L, Burke M, Fagerstrom K. Effect of smokeless tobacco (snuff) on smoking and public health in Sweden. Tob Control 2003;12:349-59.
11. Melikian AA, Hoffmann D. Smokeless tobacco: a gateway to smoking or a way away from smoking. Biomarkers 2009; Suppl 1:85-9.
12. Carlens C, Hergens MP, Grunewald J, Ekbom A, Eklund A, Hoglund CO, et al. Smoking, use of moist snuff, and risk of chronic inflammatory diseases. Am J Respir Crit Care Med 2010;181:1217-22.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
14. Hedstrom AK, Baarnhielm M, Olsson T, Alfredsson L. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 2009;73:696-701.
15. Andersson ML, Bergman S, Soderlin MK. The effect of snuff (smokeless tobacco) on disease activity and function in rheumatoid arthritis: experiences from the Better Anti-Rheumatic FarmacOTherapy, a longitudinal multicenter study on early rheumatoid arthritis. J Clin Rheumatol 2013;19:14-8.
16. Lindblad SS, Mydel P, Jonsson IM, Senior RM, Tarkowski A, Bokarewa M. Smoking and nicotine exposure delay development of collagen-induced arthritis in mice. Arthritis Res Ther 2009;11:R88.
17. Van Maanen MA, Lebre MC, van der Poll T, LaRosa GJ, Elbaum D, Vervoordeldonk MJ, et al. Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice. Arthritis Rheum 2009;60:114-22.
18. Sykes AP, Brampton C, Klee S, Chander CL, Whelan C, Parsons ME. An investigation into the effect and mechanisms of action of nicotine in inflammatory bowel disease. Inflamm Res 2000;49:311-9.
19. Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004;10:1216-21.
20. Zhou Y, Zuo X, Li Y, Wang Y, Zhao H, Xiao X. Nicotine inhibits tumor necrosis factor-α induced IL-6 and IL-8 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Rheumatol Int 2012;32:97-104.